2016, Number 6
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2016; 54 (6)
Use of chemotherapy during pregnancy
Benardete-Harari DN, Kershenovich-Gersson J, MerazÁvila D, Galnares-Olalde JA, Olaya-Guzmán EJ
Language: Spanish
References: 39
Page: 752-758
PDF size: 457.08 Kb.
ABSTRACT
The presence of malignant tumors during pregnancy complicates the
management of both tumor and pregnancy, since any diagnostic or
therapeutic intervention could imply risks that may bring on detrimental
effects to fetus or mother. The risks involved in exposing a fetus to cytotoxic
therapy are associated to gestational age and the time of in utero
exposure to that therapy. Cancer treatment has two different objectives:
local control by surgery and radiotherapy, and one that seeks to eradicate
systemic disease through chemotherapy, immunotherapy, hormone
therapy, or targeted therapies.
REFERENCES
Gabbe SG, Niebyl JR, Simpson JL, Landon MB, Galan HL, Jauniaux ERM, et al. Obstetrics: Normal and Problem Pregnancies. Sixth edition. Philadelphia, PA, USA: Elsevier; 2012. pp. 1256-1276.
Gerson R, Serrano A, Flores VF, Villalobos A. Quimioterapia en cáncer durante el embarazo. Anales Medicos. 2006;61:29-32.
DeVita VT, LawrenceTS, Rosenberg SA. Cancer: Principles & Practice of Oncology. 8th Edition. Philadelphia, PA, USA: Wolters Kluwer/Lippincott Williams & Wilkins; 2008.
Cohn D, Ramaswamy B, Blum K. Malignancy and pregnancy. In: Creasy RK, Resnik R, Iams JD, et al. (eds.). Creasy & Resnik’s maternal fetal medicine: Principles and practice. Sixth edition. Philadelphia, PA, USA: Saunders; 2009. pp. 885-904.
Muñoz MC. Uso de Quimioterapia en el embarazo (Caso clínico y revisión bibliográfica). Revista Medica de Costa Rica y Centroamérica. 2010;LXVII(592):207-10.
Perry MC. The chemotherapy source book. Fourth edition. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2008.
Amant F, Loibl S, Neven P, Van Calsteren K. Breast Cancer During Pregnancy. Lancet. 2012;379:570-9.
Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG. Williams Ginecología. Neoplasias. McGraw- Hill. 2008;13: 1193-1206.
Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012 Nov 10;30(32):4017-25. doi: 10.1200/ JCO.2012.43.5362.
Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol. 1989;28:113-21.
Nygren P; SBU-group. Swedish Council on Technology Assessment in Health Care. What is cancer chemotherapy? Acta Oncol. 2001;40(2-3):166-74.
Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 1996;32A:912-9.
Godoy-Rivera LM. Biología Molecular en cáncer. Clínicas Oncológicas de Iberoamérica. P DESA; 2008. pp. 29-36.
Jones PA. Overview of cancer epigenetics. Semin Hematol. 2005 Jul;42(3 Suppl 2):S3-8.
Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009 Jan;7(1):99-108.
Frei E 3rd, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585-94.
Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996 Sep;14(9):2590-611.
Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002 Apr 22;86(8):1297-302.
Gurney H. I don’t underdose my patients... do I? Lancet Oncol. 2005;6:637-8.
Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer. 2007 Aug 28; 97(5): 577- 81. doi: 10.1038/sj.bjc.6603925
Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8.
Theriault R, Hahn K. Management of breast cancer in pregnancy. Curr Oncol Rep. 2007 Jan;9(1):17-21.
Leslie KK, Koil C, Rayburn WF. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am. 2005 Dec;32(4):627-40.
Food and Drug Administration. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy. Disponible en volunteers.www.fda.gov/downloads/ Drugs/Guidance/UCM078932.pdf
Selig BP, Furr JR, Huey RW, Moran C, Alluri VN, Medders GR, et al. Cancer chemotherapeutic agents as human teratogens. Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):626-50. doi: 10.1002/bdra.23063.
Mir O, Berveiller P, Ropert S, Goffinet F, Goldwasser F. Use of platinum derivatives during pregnancy. Cancer. 2008 Dec 1;113(11):3069-74. doi: 10.1002/ cncr.23935.
Cancer Care Ontario, Cancer in young adults in Canada. Toronto: Cancer Care Ontario; 2006. May 2006.
Santucci AK, Gold MA, Akers AY, Borrero S, Schwarz EB. Women’s perspectives on counseling about risks for medication-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2009;88:64-9.
Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34:302-12.
Azim HA, Peccatori FA. Managing cancer during pregnancy: what evidence do we have? Pol Arch Med Wewn. 2011;121:29-34.
Leslie KK. Chemotherapy and pregnancy. Clin Obstet Gynecol. 2002;45(1):153-64.
Koren G. Fetal risks of maternal pharmacotherapy: identifying signals. Handb Exp Pharmacol. 2011;205:285-94.
Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol. 2009;113(1):166-88.
Kirshon B, Wasserstrum N, Willis R, Herman GE, Mc- Cabe ER. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol. 1988;72(3 Pt2):462-4.
Missailidis S (ed.). Anticancer therapeutics. First edition. Chichester, West Sussex, UK: John Wiley & Sons; 2008.
Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V; Society of Obstetricians and Gynaecologists of Canada. Cancer chemotherapy and pregnancy. J Obstet Gynaecol Can. 2013 Mar;35(3):263-80.
Cole S, Kantarjian H, Ault P, Cortes JE. Successful completion of pregnancy in patient with CML without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma. 2009;9(4):324-7.
Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-506.
Pentheroudakis G. Cancer and pregnancy. Ann Oncol. 2008;19(5):v38-v39.